In the biotech industry, where the demand for biologics and biosimilars is surging, Lemnisca has introduced a novel approach to address the challenges faced by manufacturers in scaling up production.
By integrating a software solution with in-house wet lab capabilities, Lemnisca leverages data to enhance the precision of its digital twin platform. This strategy represents a significant advancement in the bioprocessing industry, reshaping the way businesses recreate life’s fundamental building blocks.
The global bioprocessing sector is on a remarkable growth trajectory, projected to reach $228.73 billion by 2033. The escalating need for bio-based materials across various sectors has catalyzed India’s bio-economy, witnessing a substantial 16-fold increase to $165.7 billion in the last decade.
Recognizing the immense potential in biotech, Lemnisca’s founders, Pushkar Pendse and Shilpa Nargund, identified the critical gap between laboratory experiments and large-scale production. Their digital twin platform for fermentation is poised to empower biotech manufacturers to elevate bioprocesses to an industrial scale, enhancing the accessibility and affordability of biotech products.
This strategic approach by Lemnisca aligns with the global trend towards more efficient and scalable bioprocessing solutions, paving the way for a transformative impact on the industry’s landscape.
Source: Inc42 Media